Telomir Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 13.07 million compared to USD 0.854147 million a year ago. Basic loss per share from continuing operations was USD 0.48 compared to USD 0.03 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.96 USD | -2.22% | +6.56% | 0.00% |
07-02 | Telomir Pharmaceuticals Joins Russell 3000, Microcap Indexes | MT |
05-30 | Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1 | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 120M | |
+56.39% | 816B | |
+39.42% | 634B | |
-7.52% | 351B | |
+16.79% | 323B | |
+7.59% | 293B | |
+13.21% | 238B | |
+0.82% | 222B | |
+13.39% | 218B | |
+8.25% | 167B |
- Stock Market
- Equities
- TELO Stock
- News Telomir Pharmaceuticals, Inc.
- Telomir Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023